Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease that leads to inevitable joint destruction. The
revised American College of Rheumatology (ACR) criteria for the diagnosis of RA are not sensitive enough for
classification of the very early onset of the disease. They lack the predictive value for identifying patients at high risk
of rapid joint damage and for assessing the efficacy of treatment. To improve the situation, several new biomarkers
are currently studied to help to achieve this goal. Respecting the pathophysilogy of RA, several markers reflecting
immune response, inflammation, joint destruction, and genetic factors are discussed in this review. Finally, the
potential use of several markers in the clinical practice is depicted.
rheumatoid arthritis, joint biomarkers, inflammation, joint destruction.